论文部分内容阅读
3-羟基3-甲基戊二酰辅酶A(HMGCoA)还原酶(即CH合成限速酶)的抑制剂是近年介绍的一类独特的降胆固醇(CH)药物,它们在相对低剂量时就能显著降低血浆CH,且在短期研究中未发现有严重不良反应,为高胆固醇血症(Hch)的治疗提供了新的希望。1987年美国FDA已批准了一种HMG-CoA还原酶抑制剂Lovastatin。如果证明还原酶抑制剂无长期不良反应,它们将广泛应用于各种Hch的治疗。本文评价了目前对还原酶抑制剂作用机理的解释和治疗各种异常脂血
Inhibitors of 3-hydroxy 3-methylglutaryl coenzyme A (HMGCoA) reductase (ie, the rate-limiting enzyme for CH synthesis) are a unique class of cholesterol lowering (CH) drugs introduced in recent years that, at relatively low doses Can significantly reduce plasma CH, and in the short-term study found no serious adverse reactions, for the treatment of hypercholesterolemia (Hch) provides new hope. In 1987 the United States FDA has approved a HMG-CoA reductase inhibitor Lovastatin. If demonstrated reductase inhibitors have no long-term adverse effects, they will be widely used in the treatment of various Hchs. This article evaluates the current explanation of the mechanism of action of reductase inhibitors and the treatment of various dyslipidemic